Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Reproductive system and breast disorders – page 21

  • 956 clinical trials
  • 393 recruiting
  • 345 conditions
  • 28 countries

Conditions in this area

345 conditions with trials, the busiest first

Breast cancer168Prostate cancer101Ovarian cancer91Breast cancer metastatic84Triple negative breast cancer69Hormone receptor positive HER2 negative breast cancer62Hormone-refractory prostate cancer56Endometrial cancer53Prostate cancer metastatic48HER2 positive breast cancer42Hormone receptor positive breast cancer41Cervix carcinoma35Fallopian tube cancer30Breast cancer female27Non-small cell lung cancer25Infertility female22Hormone-dependent prostate cancer18Infertility18Ovarian cancer recurrent18Ovarian epithelial cancer18Colorectal cancer12Gastric cancer12Head and neck cancer12Malignant peritoneal neoplasm12+321

Clinical trials in Reproductive system and breast disorders

956 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

956 clinical trials

Prostate cancer

Recruiting

Comparison of Short vs Long-term Hormone Therapy with Goserelin, Leuprorelin, or Triptorelin Combined with Radiation for Prostate Cancer Patients After Surgery

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years
  • Substances:Bicalutamide
  • Sponsor:Instituto De Investigacion En Oncología Radioterapica FEOR

Endometrial cancer+3

Recruiting

Study on Olaparib and Bevacizumab for Patients with Advanced Ovarian, Fallopian Tube, or Peritoneal Cancer

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Vall D Hebron Institute Of Oncology

Seminoma

Recruiting

Study on Reducing Treatment for Stage IIa/IIb Seminoma Using Etoposide, Cisplatin, and Carboplatin in Patients with Tumors Smaller than 3 cm

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Centre Leon Berard

Breast cancer stage IV

Recruiting

Study of Pembrolizumab and Carboplatin for Patients with BRCA-Related Metastatic Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Pembrolizumab
  • Sponsor:Azienda Ospedaliero Universitaria Di Modena

Renal cancer+2

Recruiting

Study on Using EMI-137 for Intraoperative Visualization in Patients with Penile and Tongue Cancer

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ac-Ala-Gly-Ser-Cys(1)-Tyr-Cys(2)-Ser-Gly-Pro-Pro-Arg-Phe-Glu-Cys(2)-Trp-Cys(1)-Tyr-Glu-Thr-Glu-Gly-Thr-Gly-Gly-Gly-Lys(Unk)-Nh2 Conjugated To Cy5 Dye
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

HER2 positive breast cancer

Recruiting

Study on Trastuzumab, Pertuzumab, and Tucatinib for Patients with Stage II-III HER2-Positive Breast Cancer Without Chemotherapy

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting

Behcet's syndrome

Recruiting

Study on Steroid and Rivaroxaban Treatment for Deep Vein Thrombosis in Behçet's Syndrome Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Rivaroxaban
  • Sponsor:Assistance Publique Hopitaux De Paris

Triple negative breast cancer

Recruiting

Study of Capecitabine and Pembrolizumab for Patients with Triple Negative Breast Cancer After Chemoimmunotherapy and Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Unicancer

Osteoporosis postmenopausal

Recruiting

Study on Zoledronic Acid Use After Stopping Denosumab in Women with Postmenopausal Osteoporosis

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Zoledronic Acid
  • Sponsor:Centre Hospitalier Universitaire De Toulouse

Breast neoplasm

Recruiting

Study on the Effects of Selumetinib, Bicalutamide, and Olaparib in Patients with Metastatic Breast Cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bicalutamide
  • Sponsor:Istituto Europeo Di Oncologia S.r.l.

Adrenogenital syndrome

Recruiting

Study on the Effectiveness of Dexamethasone in Preventing Prenatal Virilization in Female Patients with Congenital Adrenal Hyperplasia

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years
  • Substances:Dexamethasone
  • Sponsor:Philipps-Universitaet Marburg

Breast cancer+1

Recruiting

Study on Zanidatamab and Chemotherapy for Patients with Metastatic HER2-Positive Breast Cancer After Trastuzumab Deruxtecan Treatment

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:Jazz Pharmaceuticals Ireland Limited

Substances studied in this area

The therapies tested most often in Reproductive system and breast disorders trials.

Paclitaxel118 clinical trialsCarboplatin86 clinical trialsPembrolizumab77 clinical trialsLetrozole73 clinical trialsFulvestrant58 clinical trialsDocetaxel49 clinical trialsEnzalutamide49 clinical trialsExemestane46 clinical trialsAnastrozole44 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.